Xu Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xu Zheng has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Christina Cho
Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA
1 shared publication - Gangxiong Huang
Tcelltech Biological Science and Technology, Fuzhou, China
1 shared publication - Gen-Shu Wang
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China
1 shared publication Guosheng Wang
Department of Rheumatology and Immunology The First Affiliated Hospital of USTC University of Science and Technology of China Hefei Anhui China ustc.edu.cn
1 shared publicationHui Chu
Department of Rheumatology and Immunology The First Affiliated Hospital of USTC University of Science and Technology of China Hefei Anhui China ustc.edu.cn
1 shared publicationHui Li
Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, Guangzhou, Guangdong 510630, China
1 shared publication
Latest Publications
- Open Access
- 25 January 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (2)
Ablation of T cell–associated PD-1H enhances functionality and promotes adoptive immunotherapy
Programmed death-1 homolog (PD-1H) is a coinhibitory molecule that negatively regulates T cell–mediated immune responses. In this study, we determined whether ablation of T cell–associated PD-1H could enhance adoptive T cell therapy in experimental tumor models. The expression of PD-1H is upregulated in activated and tumor-infiltrating CD8 + T cells. Activated CD8 + T cells from PD-1H–deficient (PD-1H–KO) mice exhibited increased cell proliferation, cytokine production, and antitumor activity in vitro. Adoptive transfer of PD-1H–KO CD8 + T cells resulted in the regression of established syngeneic mouse tumors. Similar results were obtained when PD-1H was ablated in T cells by CRISPR/Cas9-mediated gene silencing. Furthermore, ablation of PD-1H in CAR-T cells significantly improved their antitumor activity against human xenografts in vivo. Our results indicate that T cell–associated PD-1H could suppress immunity in the tumor microenvironment and that targeting PD-1H may improve T cell adoptive immunotherapy.
- 25 January 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (2)
Open AccessAblation of T cell–associated PD-1H enhances functionality and promotes adoptive immunotherapy
Programmed death-1 homolog (PD-1H) is a coinhibitory molecule that negatively regulates T cell–mediated immune responses. In this study, we determined whether ablation of T cell–associated PD-1H could enhance adoptive T cell therapy in experimental tumor models. The expression of PD-1H is upregulated in activated and tumor-infiltrating CD8 + T cells. Activated CD8 + T cells from PD-1H–deficient (PD-1H–KO) mice exhibited increased cell proliferation, cytokine production, and antitumor activity in vitro. Adoptive transfer of PD-1H–KO CD8 + T cells resulted in the regression of established syngeneic mouse tumors. Similar results were obtained when PD-1H was ablated in T cells by CRISPR/Cas9-mediated gene silencing. Furthermore, ablation of PD-1H in CAR-T cells significantly improved their antitumor activity against human xenografts in vivo. Our results indicate that T cell–associated PD-1H could suppress immunity in the tumor microenvironment and that targeting PD-1H may improve T cell adoptive immunotherapy.
- Open Access
- 1 January 2020
- Published by Wiley in Journal of Immunology Research
- Vol. 2020 (1)
B7‐H4 Inhibits the Development of Primary Sjögren’s Syndrome by Regulating Treg Differentiation in NOD/Ltj Mice
Background . This study is aimed at exploring the role of B7‐H4 in the pathogenesis of primary Sjögren’s syndrome (pSS) in NOD/Ltj mouse. Methods . B7‐H4 expression in salivary glands was examined by IHC, and lymphocyte infiltration was showed by H&E. Next, anti‐B7‐H4 mAb or immunoglobulin isotype was injected into NOD/Ltj mice. Cytokine levels were measured by quantitative RT‐PCR, and immunoglobulins were measured by ELISA. T cell subsets were analyzed by flow cytometry. Last, we treated NOD/Ltj mice with B7‐H4Ig and control Ig. CD4+Foxp3+ T cells were assessed by immunohistochemistry. Two‐tailed Student’s t ‐tests were used to detect the statistical difference in various measures between the two groups. Results . B7‐H4 expression was remarkably reduced in salivary glands of NOD/Ltj mice at 15 weeks compared with the NOD/Ltj mice at 8 weeks. Anti‐B7‐H4 mAb treatment increased lymphocyte infiltration in salivary glands. Inflammatory cytokines including IL‐12, IL‐18, IL‐1 α , TNF‐ α , IFN‐ α , and BAFF were upregulated markedly in anti‐B7‐H4 mAb‐treated mice compared to IgG isotype‐treated mice. Flow cytometry analysis showed that anti‐B7‐H4 mAb‐treated mice had lower levels of CD4+Foxp3+/CD4+ T cells in spleen. Moreover, Foxp3 mRNA levels of salivary glands were diminished in anti‐B7‐H4 mAb‐treated mice. Flow cytometry analysis showed that anti‐B7‐H4 mAb inhibited CD4+Foxp3+/CD4+ T cell production, while B7‐H4Ig would promote naïve CD4+ T into Treg differentiation. Administration with B7‐H4Ig displayed significantly decreased lymphocyte infiltration in salivary glands and low levels of total IgM and IgG in serum. Analysis of inflammatory cytokines in salivary glands after B7‐H4Ig treatment revealed that the mRNA levels of IL‐12, IL‐6, IL‐18, IL‐1 α , TNF‐ α , and IFN‐ α were significantly downregulated in B7‐H4Ig‐treated mice compared to control Ig treatment. B7‐H4Ig‐treated mice had significantly higher levels of CD4+Foxp3+/CD4+ T cells in spleen. IHC in salivary gland revealed that CD4+Foxp3+ T cells of B7‐H4Ig treatment mouse were more than control Ig treatment. Conclusions . Our findings implicate that B7‐H4 has a protective role for salivary gland epithelial cells (SGECs) and therapeutic potential in the treatment of pSS.
- 1 January 2020
- Published by Wiley in Journal of Immunology Research
- Vol. 2020 (1)
Open AccessB7‐H4 Inhibits the Development of Primary Sjögren’s Syndrome by Regulating Treg Differentiation in NOD/Ltj Mice
Background . This study is aimed at exploring the role of B7‐H4 in the pathogenesis of primary Sjögren’s syndrome (pSS) in NOD/Ltj mouse. Methods . B7‐H4 expression in salivary glands was examined by IHC, and lymphocyte infiltration was showed by H&E. Next, anti‐B7‐H4 mAb or immunoglobulin isotype was injected into NOD/Ltj mice. Cytokine levels were measured by quantitative RT‐PCR, and immunoglobulins were measured by ELISA. T cell subsets were analyzed by flow cytometry. Last, we treated NOD/Ltj mice with B7‐H4Ig and control Ig. CD4+Foxp3+ T cells were assessed by immunohistochemistry. Two‐tailed Student’s t ‐tests were used to detect the statistical difference in various measures between the two groups. Results . B7‐H4 expression was remarkably reduced in salivary glands of NOD/Ltj mice at 15 weeks compared with the NOD/Ltj mice at 8 weeks. Anti‐B7‐H4 mAb treatment increased lymphocyte infiltration in salivary glands. Inflammatory cytokines including IL‐12, IL‐18, IL‐1 α , TNF‐ α , IFN‐ α , and BAFF were upregulated markedly in anti‐B7‐H4 mAb‐treated mice compared to IgG isotype‐treated mice. Flow cytometry analysis showed that anti‐B7‐H4 mAb‐treated mice had lower levels of CD4+Foxp3+/CD4+ T cells in spleen. Moreover, Foxp3 mRNA levels of salivary glands were diminished in anti‐B7‐H4 mAb‐treated mice. Flow cytometry analysis showed that anti‐B7‐H4 mAb inhibited CD4+Foxp3+/CD4+ T cell production, while B7‐H4Ig would promote naïve CD4+ T into Treg differentiation. Administration with B7‐H4Ig displayed significantly decreased lymphocyte infiltration in salivary glands and low levels of total IgM and IgG in serum. Analysis of inflammatory cytokines in salivary glands after B7‐H4Ig treatment revealed that the mRNA levels of IL‐12, IL‐6, IL‐18, IL‐1 α , TNF‐ α , and IFN‐ α were significantly downregulated in B7‐H4Ig‐treated mice compared to control Ig treatment. B7‐H4Ig‐treated mice had significantly higher levels of CD4+Foxp3+/CD4+ T cells in spleen. IHC in salivary gland revealed that CD4+Foxp3+ T cells of B7‐H4Ig treatment mouse were more than control Ig treatment. Conclusions . Our findings implicate that B7‐H4 has a protective role for salivary gland epithelial cells (SGECs) and therapeutic potential in the treatment of pSS.
- Open Access
- 3 December 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1-10
Mesenchymal Stem Cells Ameliorate Hepatic Ischemia/Reperfusion Injury via Inhibition of Neutrophil Recruitment
Ischemia/reperfusion injury (IRI) remains a major problem in organ transplantation, which represents the main cause of graft dysfunction posttransplantation. Hepatic IRI is characterized by an excessive inflammatory response within the liver. Mesenchymal stem cells (MSCs) have been shown to be immunomodulatory cells and have the therapeutic action on IRI in several organs. However, the mechanism of regulatory effect of MSCs on IRI remains unclear. In the present study, we examined the impact of MSCs on hepatic inflammatory response such as neutrophil influx and liver damage in a rat model of 70% hepatic IRI. Treatment with MSCs protected rat against hepatic IRI, with significantly decreased serum levels of liver enzymes, attenuated hepatic neutrophil infiltration, reduced expression of apoptosis-associated proteins, and ameliorated liver pathological injury. MSCs also significantly enhanced the intracellular activation of p38 MAPK phosphorylation, which led to decreased expression of CXCR2 on the surface of neutrophils. In addition, MSCs significantly diminished neutrophil chemoattractant CXCL2 production by inhibiting NF-κB p65 phosphorylation in macrophages. These results demonstrate that MSCs significantly ameliorate hepatic IRI predominantly through its inhibitory effect on hepatic neutrophil migration and infiltration.
- 3 December 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1-10
Open AccessMesenchymal Stem Cells Ameliorate Hepatic Ischemia/Reperfusion Injury via Inhibition of Neutrophil Recruitment
Ischemia/reperfusion injury (IRI) remains a major problem in organ transplantation, which represents the main cause of graft dysfunction posttransplantation. Hepatic IRI is characterized by an excessive inflammatory response within the liver. Mesenchymal stem cells (MSCs) have been shown to be immunomodulatory cells and have the therapeutic action on IRI in several organs. However, the mechanism of regulatory effect of MSCs on IRI remains unclear. In the present study, we examined the impact of MSCs on hepatic inflammatory response such as neutrophil influx and liver damage in a rat model of 70% hepatic IRI. Treatment with MSCs protected rat against hepatic IRI, with significantly decreased serum levels of liver enzymes, attenuated hepatic neutrophil infiltration, reduced expression of apoptosis-associated proteins, and ameliorated liver pathological injury. MSCs also significantly enhanced the intracellular activation of p38 MAPK phosphorylation, which led to decreased expression of CXCR2 on the surface of neutrophils. In addition, MSCs significantly diminished neutrophil chemoattractant CXCL2 production by inhibiting NF-κB p65 phosphorylation in macrophages. These results demonstrate that MSCs significantly ameliorate hepatic IRI predominantly through its inhibitory effect on hepatic neutrophil migration and infiltration.